Novel membrane-permeable contrast agent for brain tumor detection by MRI

Area of Science:

• Biomedical Imaging
• Nanotechnology
• Oncology

Background:

• Early detection of brain tumors is crucial for effective cancer therapy.
• Monitoring tumor progression and treatment outcomes is vital due to the aggressive nature of brain cancer.
• Current imaging methods face challenges in detecting small, early-stage brain lesions.

Purpose of the Study:

• To design and evaluate a novel membrane-permeant contrast agent for enhanced brain tumor detection.
• To assess the agent's ability to delineate tumors in vitro and in vivo.
• To explore the potential of the agent for noninvasive monitoring of brain cancer.

Main Methods:

• Development of a novel contrast agent (MN-MPAP-Cy5.5) combining a superparamagnetic iron oxide core, myristoylated polyarginine peptides, and Cy5.5 dye.
• In vitro evaluation of cellular uptake in U-87 human glioma cells.
• In vivo assessment of tumor localization and delineation using MRI in a rodent model.

Main Results:

• The novel contrast agent demonstrated remarkable uptake by glioma cells in vitro.
• The agent successfully localized and delineated stereotactically injected tumors in vivo via MRI.
• Evidence suggests the agent translocates across leaky tumor vasculature and accumulates in tumor cells.

Conclusions:

• The developed contrast agent exhibits promising properties for early and noninvasive brain tumor detection.
• The membrane translocation capability of the agent enhances its accumulation in tumor cells.
• This approach offers an improved strategy for detecting brain lesions and monitoring cancer pathology.